75 岁女性,高血压,既往 TIA → 6 分,推荐抗凝 A(≥75)=2 + Sc=1 + H=1 + S₂(卒中/TIA)=2 → 总分 6。女性≥3 → 推荐口服抗凝(首选 DOAC)。年卒中风险约 13.6%。{"result":"CHA₂DS₂-VASc total 6. Recommend oral anticoagulation (DOAC preferred over warfarin). Approx. annual stroke risk ~13.6%.","metadata":{"input":{"ageGroup":"gte75","sex":"female","chf":false,"hypertension":true,"diabetes":false,"stroke":true,"vascular":false},"result":{"total":6,"components":{"age":2,"sex":1,"chf":0,"hypertension":1,"diabetes":0,"stroke":2,"vascular":0},"sexOnlyPoint":false,"annualStrokeRiskPercent":13.6,"recommendation":{"category":"Recommend anticoagulation","recommendation":"Recommend oral anticoagulation; DOAC preferred over warfarin."},"method":"CHA₂DS₂-VASc (Lip 2010 Chest; 2023 ACC/AHA/ACCP/HRS)","model":"Lip GY et al. Chest 2010;137(2):263-272. Not medical advice."}}}
A(65–74)=1。男性 1 → 可考虑抗凝(共同决策)。年卒中风险约 0.6%。{"result":"CHA₂DS₂-VASc total 1. Consider oral anticoagulation (DOAC preferred) using shared decision-making. Approx. annual stroke risk ~0.6%.","metadata":{"input":{"ageGroup":"65to74","sex":"male","chf":false,"hypertension":false,"diabetes":false,"stroke":false,"vascular":false},"result":{"total":1,"components":{"age":1,"sex":0,"chf":0,"hypertension":0,"diabetes":0,"stroke":0,"vascular":0},"sexOnlyPoint":false,"annualStrokeRiskPercent":0.6,"recommendation":{"category":"Consider anticoagulation","recommendation":"Consider oral anticoagulation (DOAC preferred over warfarin) using shared decision-making, balanced against bleeding risk (HAS-BLED) and patient preference."},"method":"CHA₂DS₂-VASc (Lip 2010 Chest; 2023 ACC/AHA/ACCP/HRS)","model":"Lip GY et al. Chest 2010;137(2):263-272. Not medical advice."}}}